Management of early-stage metastatic prostate cancer: appraisal of locoregional treatments and radiation therapy, with or without immunomodulation. Issue 8 (15th July 2021)

• Record Type: Journal Article
• Authors: Sandoval, Maria L; Dohm, Ammoren; Yamoah, Kosj
• Is Part Of: Endocrine-related cancer. Volume 28:Issue 8(2021)
• Page Start: T109
• Page End: T120
• Publication Date: 2021-07-15
• Subjects: prostate cancer -- endocrine therapy -- radiotherapy -- locally advanced; Endocrine glands -- Cancer -- Periodicals; Endocrinology -- Periodicals; Cancer -- Endocrine aspects -- Periodicals; 616.9944005
• DOI: 10.1530/ERC-21-0073
• Languages: English
• ISSNs: 1351-0088

Abstract

Abstract : The current standard for the management of locally advanced and early stage metastatic prostate cancer relies on a backbone of androgen deprivation therapy (ADT) combined with radiotherapy (RT), a regimen that at a glance appears relatively straightforward. The emergence of newer diagnostic, genomic and imaging modalities have allowed for better disease risk-stratification and opened avenues for the development of more patient-centered treatment strategies. This review aims to highlight the central role of RT as part of a multi-modal approach and discuss established and emerging data for the management of locally advanced disease, biochemical recurrence, and oligometastatic disease, as well as the use of immunotherapies and radio-isotopes. This review will also briefly discuss ongoing clinical trials that provide new insights into the paradigm shift in the management of locally advanced prostate cancer.